Loading…
citypharma.us was cited for unlawfully selling unapproved and misbranded drugs over the internet, specifically opioids, benzodiazepines, and Schedule II stimulants, in violation of the Federal Food, Drug, and Cosmetic Act sections 301(a), 301(d), 301(k), 503(b), and 505(a). The company's website introduced these controlled substances into interstate commerce without FDA approval and without proper labeling, posing significant public health risks given the ongoing opioid epidemic and the acknowledged abuse potential of benzodiazepines and stimulants. The FDA emphasized the particular danger of easy internet availability of opioids and the severe medical outcomes associated with polysubstance use involving benzodiazepines and other drugs.